281 related articles for article (PubMed ID: 34034326)
1. 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer.
Fu H; Fu J; Huang J; Pang Y; Chen H
Clin Nucl Med; 2021 Nov; 46(11):940-942. PubMed ID: 34034326
[TBL] [Abstract][Full Text] [Related]
2.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
3. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
4. FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177 Lu-FAPI-46.
Fu H; Huang J; Sun L; Wu H; Chen H
Clin Nucl Med; 2022 Oct; 47(10):906-907. PubMed ID: 35485857
[TBL] [Abstract][Full Text] [Related]
5. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
6. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.
Çermik TF; Ergül N; Yılmaz B; Mercanoğlu G
Clin Nucl Med; 2022 Apr; 47(4):e333-e339. PubMed ID: 35085165
[TBL] [Abstract][Full Text] [Related]
7.
Chen Y; Zheng S; Zhang J; Yao S; Miao W
Ann Nucl Med; 2022 Jul; 36(7):610-622. PubMed ID: 35551610
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
9. [
Mu X; Huang X; Jiang Z; Li M; Jia L; Lv Z; Fu W; Mao J
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1205-1215. PubMed ID: 36495325
[TBL] [Abstract][Full Text] [Related]
10. The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.
Shu Q; Deng M; Hu M; Liu M; Chen X; Chen Y; Cai L
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1442-1452. PubMed ID: 36609606
[TBL] [Abstract][Full Text] [Related]
11. Positron Emission Tomography/Computed Tomography in Thyroid Cancer.
Bal C; Chakraborty D; Khan D
PET Clin; 2022 Apr; 17(2):265-283. PubMed ID: 35256297
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
13. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.
Kist JW; de Keizer B; Stokkel MP; Hoekstra OS; Vogel WV;
BMC Cancer; 2014 Jun; 14():405. PubMed ID: 24906384
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
15. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
16. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
19. RADIOISOTOPE DIAGNOSTIC ALGORITHM FOR THE RELAPSE AND METASTASES DETECTION IN THE IODINE-NEGATIVE DIFFERENTIATED THYROID CANCER.
Solodyannikova OI; Kmetyuk YV; Danilenko VV; Sukach GG
Probl Radiac Med Radiobiol; 2020 Dec; 25():579-591. PubMed ID: 33361863
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.
Tatar G; Beyhan E; Erol Fenercioğlu Ö; Arslan E; Çermik TF
Clin Nucl Med; 2022 Sep; 47(9):e596-e599. PubMed ID: 35930714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]